Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs

被引：0
|
作者：
Lee, S. H. [1 ]
Park, M. J. [1 ]
Chang, B. [1 ]
机构：
[1] Kyung Hee Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-TKIs; programmed death ligand; Clinical outcome;
D O I：
10.1016/j.jtho.2019.08.1195
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-44
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [31] Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
    Wang, Q-A.
    Yang, C. T.
    Kuo, C-H. S.
    Hsu, P-C.
    Chang, J. W-C.
    Wu, C-E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1694 - S1694
  • [32] Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Mutated NSCLC
    Liu, S.
    Wu, F.
    Zhang, X.
    Li, X.
    Zhao, C.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S590 - S590
  • [33] Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
    Jia, Yijun
    Li, Xuefei
    Zhao, Chao
    Ren, Shengxiang
    Su, Chunxia
    Gao, Guanghui
    Li, Wei
    Zhou, Fei
    Li, Jiayu
    Zhou, Caicun
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [34] Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice
    Jia, Yijun
    Zhao, Sha
    Jiang, Tao
    Li, Xuefei
    Zhao, Chao
    Liu, Yiwei
    Han, Ruoshuang
    Qiao, Meng
    Liu, Sangtian
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 137 : 85 - 93
  • [35] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [36] Cell-free DNA from EGFR-mutated lung cancer cells treated with EGFR-TKIs engages in innate immune signaling pathways
    Shiiya, Akihiko
    Noguchi, Takuro
    Ariga, Shin
    Ohhara, Yoshihito
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Akita, Hirotoshi
    CANCER SCIENCE, 2022, 113 : 835 - 835
  • [37] Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma
    Zhu, Hui
    Ma, Xiaoyan
    Yu, Jinming
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1484 - S1484
  • [38] Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
    Ma, Xiaoyan
    Zhu, Hui
    Guo, Hongbo
    Han, Anqin
    Wang, Haiyong
    Jing, Wang
    Zhang, Yan
    Kong, Li
    Yu, Jinming
    ONCOTARGET, 2016, 7 (49) : 81906 - 81917
  • [39] Randomized Double-blind Placebo-controlled trial of Nicotinamide and EGFR-TKIs for EGFR-mutated Lung Adenocarcinoma
    Kim, Y. -C.
    Oh, I. -J.
    Park, C. -K.
    Oh, H. -J.
    Park, I. Y.
    Bae, S. -C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S442 - S443
  • [40] High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs
    Liu, J.
    Itchins, M.
    Nagrial, A.
    Cooper, W.
    De Silva, M.
    Barnet, M.
    Varikatt, W.
    Sivasubramaniam, V.
    Davis, A.
    Gill, A.
    Blinman, P.
    Lee, K.
    Hui, R.
    Gao, B.
    Pavlakis, N.
    Clarke, S.
    Lee, J.
    Boyer, M.
    Kao, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S588 - S589
12345